

- Amyloidosis (Cont.):**
 lichenoid, 365
 localized, 720t
 macular, 365
 in monoclonal gammopathy of uncertain significance, 721
 in multiple myeloma, 721, 1567
 nodular, 365
 pathogenesis of, 721, 2642
 prognosis of, 1567
 senile, 1467, 1566
 small-intestinal mucosal biopsies in, 1939, 1940t
 systemic, 720t
 treatment of, 721–723, 724, 1845
- Amyloid plaques**
 in AD, 76, 172t, 444e–8f, 444e–10
 in Creutzfeldt-Jakob disease, 453e–4
- Amyloid polyneuropathy, familial,** 2681
- Amyloid precursor protein (APP)**
 in AD, 444e–10, 453e–6, 2600, 2600f
 in amyloidosis, 719
 in neurodegenerative disease, 444e–9
- Amyolytic enzymes,** 2090
- Amyotrophic lateral sclerosis (ALS), 2631**
 clinical features of, 2632–2633
 diagnosis of, 2632–2633
 differential diagnosis of, 2633
 dysphagia in, 256, 257
 epidemiology of, 2633
 familial, 437, 444e–9, 2633, 2634t
 frontotemporal dementia and, 2633, 2635t
 genetic considerations in, 444e–1, 444e–9, 2634t
 imaging in, 2632f
 juvenile-onset, 2636
 parkinsonism and, 2633, 2635t
 pathogenesis of, 2633, 2635
 pathology of, 2631–2632, 2632f
 treatment of, 90e–3, 2633
- Amyotrophic lateral sclerosis (ALS)/parkinsonian/dementia complex of Guam,** 2608
- Amyotrophy,** 2632
- ANA. See Antinuclear antibodies (ANA)**
- Anabolic-androgenic steroid (AAS) abuse**
 adverse effects of, 7e–2–4, 7e–3t, 2374
 cardiovascular, 2374
 cholestasis, 284
 edema, 253t
 hepatotoxicity, 2029
 hirsutism, 380
 long-term, 2374
 diagnosis of, 7e–3–4, 7e–3t, 2374
 epidemiology of, 7e–2, 2374
 treatment of, 7e–4
 withdrawal symptoms, 2374
- Anaerobic bacteria, 1094**
 antibiotic resistance in, 1101–1102, 1101t
 antibiotic susceptibility testing of, 1101
 in normal human microbiota, 1094–1095, 1095t
 specimen handling, 1100
 virulence factors of, 1096
- Anaerobic bacterial infections, mixed, 1094**
 approach to the patient, 1096–1097
 clinical features of
 bacteremia, 1100
 bone and joint, 1099–1100
 in burn wounds, 166e–1
 with clostridial involvement, 990–991, 991t
 CNS, 1098
 in dog-bite wounds, 167e–1
 endocarditis and pericarditis, 1100
 in human bite-wounds, 167e–2
 intraabdominal, 1099, 1102
 mouth, head, and neck, 1097, 1102
 pelvic, 1099
 pleuropulmonary, 1098–1099, 1098f
 skin and soft tissue, 1099
 definitions in, 1094
 diagnosis of, 150e–5t, 1100
 epidemiology of, 1097
 etiology of, 1095–1096
 pathogenesis of, 1096
 supportive measures, 1102
 treatment of, 1101–1102, 1101t
- Anaerobic glycolysis,** 461
- Anagen, 331**
- Anagen effluvium,** 354, 379
- Anagliptin,** 2414t
- Anagrelide,** 674, 678
- Anajatuba virus,** 1307t
- Anakinra**
 action of, 372e–30
 adverse effects of, 2146t
 for calcium apatite deposition disease, 2237
 for calcium pyrophosphate deposition disease, 2236
 for familial Mediterranean fever, 2214
 for fever of unknown origin, 141
 for gout, 2234
 indications for, 372e–8t, 2147
 for rheumatoid arthritis, 2146t, 2147
- Anal cancer,** 351, 543–544, 1198, 1199
- Anal fissures, 1978**
- Anal fistula, 1111, 1978**
- Analgesia (sensory abnormality), 158**
- Analgesics**
 adverse effects of, 1861, 1861f
 for lumbar puncture, 443e–1–2
 medication-overuse headache and, 109, 2593
 urinary, 867
- Anal intercourse, HIV infection risk and,** 1221
- Anal reflex,** 2539
- Anal sphincter,** 265f
- Anaphylactic reactions. See also Hypersensitivity reactions**
 to dialyzer, 1824
 drug-induced, 381
 to insect stings, 2749
 to transfusion, 138e–5
- Anaphylaxis, 2116**
 clinical features of, 2116
 definition of, 2116
 diagnosis of, 2116–2117
 drug-induced, 381
 etiology of, 2116
 exercise-induced, 2118, 2119
 pathophysiology of, 2116
 predisposing factors for, 2116
 prevention of, 2117
 respiratory acidosis in, 322–323
 treatment of, 2117, 2749
- Anaplasma spp. infections,** 888, 1152, 1160.
See also Human granulocytic anaplasmosis
- Anaplastic large T/null cell lymphoma,** 102e–5t, 699t, 702t, 707
- Anaplastic thyroid cancer,** 2307
- Anasarca,** 251
- Anastrozole,** 103e–15
- Anatomic dead space,** 306e–3
- ANCA. See Antineutrophil cytoplasmic antibodies (ANCA)**
- Anchoring heuristic,** 19
- Ancylostoma braziliense,** 245e–3t, 1415. *See also* Larva migrans, cutaneous
- Ancylostoma caninum,** 1415. *See also* Larva migrans, cutaneous
- Ancylostoma duodenale,** 245e–3t, 1414, 1414t.
See also Hookworm infections
- Andersen syndrome (type IV GSD),** 433e–2t, 462e–14
- Andersen-Tawil syndrome,** 462e–17t, 462e–18
- Andersson lesions,** 840
- Andes virus,** 1307t
- Androgen(s)**
 abuse of. *See* Anabolic-androgenic steroid (AAS) abuse
 action and metabolism of, 2359, 2359f.
See also Androgen insensitivity syndrome (AIS)
 adrenal, for adrenal insufficiency, 2327
 adverse effects of, 378
 body fat distribution and, 6e–4
 excess of, 332–333
 in hair growth and differentiation, 331–332
 synthesis of
 disorders of, 2353, 2354t
 pathways of, 2309f, 2355f, 2358–2359, 2358f, 2359f
- Androgen blockade. See Androgen deprivation therapy (ADT)**
- Androgen deficiency**
 age-related, 7e–1
 approach to the patient, 2368f, 2369
 diagnosis of, 2369
 gynecomastia and, 2366
 in rheumatoid arthritis, 2139
 treatment of, **2369.** *See also* Testosterone therapy
- Androgen-depletion syndrome,** 585
- Androgen deprivation therapy (ADT)**
 adverse effects of, 7e–5–6, 7e–5f, 585
 approach to the patient, 7e–6, 7e–6t
 for hirsutism, 334
 intermittent use of, 586
 for prostate cancer, 103e–15, 585–586
- Androgen insensitivity syndrome (AIS), 2353**
 amenorrhea in, 335
 clinical features of, 2354–2355, 2354t
 complete, 2353–2354
 genetic considerations in, 335, 431t, 2354, 2366
 gynecomastia due to, 2366
 partial, 2355
 testicular dysfunction due to, 2366
 treatment of, 336
- Androgen receptors,** 102e–7, 431t, 2354t, 2359
- Androgen therapy. See also Testosterone therapy**
 adverse effects of, 380
 carcinogenicity, 477t
 cholestasis, 2025t
 cutaneous, 352
 monitoring of, 2372–2374, 2373t
 for aplastic anemia, 667
 for breast cancer, 530t
 contraindications to, 2372, 2372t
 for female sexual dysfunction, 331
 indications for, 2371–2372
 novel formulations of, 2371
 recommended regimens, 2372
- Andropause,** 2367
- Androstenedione,** 332, 2757t
- Anemia, 393. See also specific types**
 in acute kidney injury, 1807, 1810
 after kidney transplantation, 1831
 after liver transplantation, 2072
 approach to the patient, **393**
 from blood loss, 399, 662
 chemotherapy-related, 103e–24–25
 in chronic kidney disease. *See* Chronic kidney disease (CKD), hematologic abnormalities in
 classification of, 398, 398f
 clinical features of, 393
 in colorectal cancer, 541
 in critically ill patient, 1735
 diagnosis of, **393**
 bone marrow examination, 397
 initial workup, 393–394, 394t
 iron supply and storage tests, 397
 peripheral blood smear, 394, 394–396f.
See also Peripheral blood smear reticulocyte count in, 394, 396–397, 396t, 397t
 dyspnea in, 47e–1t, 47e–2, 47e–2t
 in endocrine deficiency states, 630
 endoscopic findings in, 1896, 1897f
 erythropoietin in, 392f
 in gastrointestinal bleeding, 276
 in heart failure, 1514
 hemolytic. *See* Hemolytic anemia
 history in, 393
 in HIV infection, 1262
 in hypometabolic states, 630–631, 630t
 hypoproliferative, 398, 625, **630**, 631.
See also Aplastic anemia; Iron-deficiency anemia